CD19 and neoplasm: Targeting these antigens can result in on-target/off-tumor toxicity.37 CAR T cell therapy has been greatly successful in the treatment of some types of hematological malignancies by targeting CD19,38 a TAA expressed on both healthy and malignant B cells.